Grace Therapeutics develops reformulated medicines for rare diseases, led by an injectable form of nimodipine for patients with brain bleeding. GRCE reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Whale Options Flow
90DNo whale options trades in GRCE in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRCE is in one of them and how their past GRCE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GRCE in an article yet. Here's the latest on the wider market.
About Grace Therapeutics
Grace Therapeutics is a pharmaceutical company based in Princeton, New Jersey, that develops reformulated versions of existing medicines for rare and orphan diseases. Its lead candidate, GTx-104, is an injectable form of nimodipine designed for intravenous delivery to patients with aneurysmal subarachnoid hemorrhage, a type of stroke. Its target customers include hospitals, physicians and patients. Its product candidates are still in development and have not yet been approved for sale.
- Headquarters
- Princeton, NJ